The best indicator for Injective (INJ)
We backtested 382 indicators across daily, weekly and hourly charts on real Injective (INJ) history. Here's what actually worked — risk-adjusted over the full backtest, with costs, and checked out-of-sample.
Where Injective (INJ) stands
Computed from our own daily OHLCV history, not quoted from a third party. Moving averages use closing prices; "52-week" is the last 252 trading sessions.
Holt Double-Exp MA
On the weekly chart, this is the strongest risk-adjusted edge we found for Injective (INJ) over ~6.0 years — beating buy-and-hold by 62.3% CAGR.
Injective (INJ) on the weekly chart
The timeframe our backtest found best for this asset. The chart is live market data; the results above are hypothetical and historical.
Chart by TradingView. Loading it contacts tradingview.com, which may set its own cookies — see our privacy policy.
Best multi-indicator combo
Going long only when all 3 agree was the strongest confluence setup we found for Injective (INJ) — trailing buy-and-hold by 2.9% CAGR, out-of-sample. Fewer, higher-conviction trades than any single indicator.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | Holt Double-Exp MA ✓ | Weekly | 104.4% | 1.22 | -80.4% | 54.5% | 22 | 62.3% |
| 2 | Ehlers SuperSmoother ✓ | Weekly | 106.3% | 1.19 | -76.0% | 42.9% | 42 | 64.2% |
| 3 | ROC (5) ✓ | Weekly | 101.5% | 1.18 | -73.7% | 40.7% | 27 | 59.4% |
| 4 | Perfect Trend Line ✓ | Weekly | 96.0% | 1.17 | -77.5% | 51.5% | 33 | 53.9% |
| 5 | Kaufman Adaptive MA ✓ | Weekly | 92.1% | 1.14 | -70.8% | 58.8% | 17 | 50.0% |
| 6 | Woodie Pivots ✓ | Weekly | 93.7% | 1.14 | -85.1% | 46.2% | 65 | 51.6% |
| 7 | Range Filter ✓ | Weekly | 78.0% | 1.13 | -38.0% | 66.7% | 18 | 35.9% |
| 8 | Gaussian Channel ✓ | Weekly | 88.2% | 1.12 | -69.0% | 33.3% | 18 | 46.1% |
| 9 | Bandpass Oscillator ✓ | Weekly | 91.0% | 1.12 | -64.0% | 46.7% | 15 | 48.9% |
| 10 | Ehlers Stochastic ✓ | Daily | 74.4% | 1.1 | -80.8% | 53.1% | 49 | 44.4% |
| 11 | Stochastic Fast (5,3) ✓ | Weekly | 86.8% | 1.1 | -81.7% | 52.4% | 42 | 44.6% |
| 12 | Regularized EMA ✓ | Weekly | 83.8% | 1.09 | -68.4% | 35.3% | 17 | 41.7% |
| 13 | Delta Volume Rising (CVD proxy) | Weekly | 78.4% | 1.08 | -90.6% | 51.9% | 27 | 36.3% |
| 14 | Vortex (7) ✓ | Weekly | 79.7% | 1.06 | -76.7% | 45.0% | 20 | 37.6% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
The question doesn't apply here. Buy-and-hold on Injective (INJ) lost money across the out-of-sample window in 336 of 336 tests, so there is no positive benchmark to lever toward — clearing a negative bar is a much weaker claim than beating a real one, and we keep the two apart rather than counting it as a win. How we compute that
For Injective (INJ), Holt Double-Exp MA on the weekly timeframe gave the best balance of return and risk in our test. It beat buy-and-hold — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More crypto
Get alerted when Injective’s signal flips
We track Injective daily. Its backtested best indicator, Holt Double-Exp MA (Weekly), is flat right now — we'll email you the moment that changes. Free, no spam, unsubscribe any time.